UroGen Pharma Ltd.
For the period ended Dec 31, 2025. Filed Mar 2, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 2, 2026
URGN$26.31+6.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Shareholders’ Deficit
(in thousands, except share amounts)
| Ordinary Shares · Additional Paid-in Capital · Accumulated Deficit · Accumulated Other Comprehensive Income (Loss) · Total | ||||||
|---|---|---|---|---|---|---|
| Number of Shares · Amount · Amounts | ||||||
| Balance as of December 31, 2023 | 32,490,119 | $89 | $614,035 | $(679,348) | $12 | $(65,212) |
| Exercise of options into ordinary shares | 419,731 | 1 | 320 | 321 | ||
| Share-based compensation | 13,108 | 13,108 | ||||
| Issuance of pre-funded warrants, net of issuance costs | 18,641 | 18,641 | ||||
| Issuance of ordinary shares, net of issuance costs | 9,321,896 | 25 | 151,144 | 151,169 | ||
| Other comprehensive income | 44 | 44 | ||||
| Net loss | (126,874) | (126,874) | ||||
| Balance as of December 31, 2024 | 42,231,746 | $115 | $797,248 | $(806,222) | $56 | $(8,803) |
| Exercise of options into ordinary shares | 750,202 | 2 | 1,970 | 1,972 | ||
| Share-based compensation | 11,959 | 11,959 | ||||
| Conversion of pre-funded warrants into ordinary shares | 3,206,271 | 9 | (6) | 3 | ||
| Issuance of ordinary shares, net of issuance costs | 2,162,053 | 7 | 42,919 | 42,926 | ||
| Other comprehensive loss | (37) | (37) | ||||
| Net loss | (153,494) | (153,494) | ||||
| Balance as of December 31, 2025 | 48,350,272 | $133 | $854,090 | $(959,716) | $19 | $(105,474) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.